At 0.59x book, HDB sits below every peer except Bradesco (0.86x) is actually higher, leaving HDB as the cheapest name in the comparison set on price-to-tangible-equity grounds. That discount would normally signal the market pricing in a ROTCE shortfall, and the reported quarterly ROE band of 2.2-7.0% (approximately 12-25% annualized depending on quarter) makes a full peer-multiple re-rating dependent on demonstrating sustained earnings power. The reported 6.2% dividend yield, above ICICI's 0.8% and Itaú's comparison, may be read as either a value signal or a capital-return posture that investors should test against payout sustainability given that one disclosed dividend outflow ($217.9B in 2026Q4) exceeded that quarter's net income.

Standard bank DuPont logic (ROE ≈ NIM × asset utilization × equity multiplier) suggests HDB's return profile is not margin-driven: ROA of 0.3-0.9% and NIM near 0.9% imply thin spread economics, while the equity multiplier rose from roughly 5.5x (0.18 equity/assets) to roughly 8.3x (0.12) as an ~$8T asset build outran equity accretion. Fee income has been a volatile swing factor rather than a stabilizer, per reported income statements, with two quarters printing negative non-interest income and one exceeding 53%, which weakens confidence in the fee-driven quality of earnings. For a franchise that historically justified premium valuation on deposit-funded growth, an ROE trajectory dependent on balance-sheet leverage is a materially lower-quality earnings mix than headline ROE alone suggests.

A near-flat 0.9% NIM through a period of significant balance-sheet growth implies the bank has largely offset deposit repricing with asset yield management, but the growth of the securities portfolio ($33.3T to $46.9T) alongside contracting cash balances suggests part of that yield maintenance may come from shifting asset mix rather than core lending spreads. The efficiency ratio failing to trend lower despite balance-sheet scale is notable: best quarters (43.6-45.8%) alternate with 62-64% prints, which may indicate seasonal cost recognition or inconsistent expense classification rather than genuine operating leverage. Given the disclosed 58.2% efficiency in 2027Q2, the cost-income structure still appears competitive versus weaker peers, but the volatility warrants close monitoring before assuming a structural cost advantage.

Regulatory capital ratios (CET1, Tier 1, total capital) are not disclosed in the available data, so direct assessment of Basel headroom is unavailable; the equity/assets proxy, however, shows a clear one-third compression in the capital cushion supporting an ~26% liability expansion. Interpreted alongside the front-loaded provision cycle ($21.0B rising to $152.9B in 2026Q1 before normalizing to $42.0B), this suggests future reserve rebuilds would fall on a thinner equity base, potentially amplifying any ROE sensitivity to credit normalization. Investors should treat the reported ratios as directional indicators rather than substitutes for disclosed regulatory capital, and monitor whether the balance-sheet expansion continues to run ahead of retained earnings.